Alterity Therapeutics
ATHE
13 hedge funds and large institutions have $481K invested in Alterity Therapeutics in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
109% more capital invested
Capital invested by funds: $230K → $481K (+$251K)
7% less funds holding
Funds holding: 14 → 13 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$118K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$43.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GBA
Garrison Bradford & Associates
New York
|
-$47K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$20.6K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$2.04K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.58K |
| 5 |
AIG
American International Group
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $383K | +$118K | +3,065 | +61% |
|
|
VKH
2
Virtu KCG Holdings
New York
| $53K | +$43.3K | +1,126 | New |
|
|
3
Bank of America
Charlotte,
North Carolina
| $17K | -$1.58K | -41 | -10% |
|
4
Wells Fargo
San Francisco,
California
| $8K | – | – | – |
|
|
AIM
5
Advantage Investment Management
Cedar Rapids,
Iowa
| $7K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $3K | -$20.6K | -537 | -90% |
|
|
7
Group One Trading
Chicago,
Illinois
| $3K | -$2.04K | -53 | -50% |
|
|
AG
8
Advisor Group
Phoenix,
Arizona
| $3K | +$3.54K | +92 | New |
|
|
MFS
9
MSI Financial Services
Springfield,
Massachusetts
| $2K | – | – | – |
|
10
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $2K | – | – | – |
|
|
GBA
11
Garrison Bradford & Associates
New York
| – | -$47K | -1,656 | Closed |
|
|
AIG
12
American International Group
New York
| – | -$1K | -42 | Closed |
|
ATHE Hedge Fund Activity: Q2 2016 in Review
13 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q2 2016, worth a combined $481K — up 109% from $230K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ATHE and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $118K. The largest seller was Garrison Bradford & Associates, exiting entirely with an estimated $47K sold.
- 13 institutional investors held Alterity Therapeutics (ATHE) as of Q2 2016, down from 14 in Q1 2016.
- Funds reported $481K of Alterity Therapeutics stock for Q2 2016, up 109% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q2 2016 and 3 closed out, a net change of -1 holder.
- The largest Alterity Therapeutics buyer in Q2 2016 was Morgan Stanley, an estimated $118K added.
- The largest Alterity Therapeutics seller in Q2 2016 was Garrison Bradford & Associates, an estimated $47K sold.
Based on aggregated 13F filings for Q2 2016.